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DAAs

:   direct acting antivirals

HCC

:   hepatocellular carcinoma

NHS

:   National Health Service

PWID

:   people who inject drugs

QALYs

:   quality‐adjusted life‐years

SVR

:   sustained virologic response

1. INTRODUCTION {#jvh12847-sec-0001}
===============

The detriment to health and cost to health services caused by liver damage arising from chronic hepatitis C virus (HCV) infection are important determinants of the cost‐effectiveness of interventions to avert HCV transmission, and of treatment strategies targeted at different stages of disease. There is uncertainty in disease progression rates, and health detriment and costs of treatment associated with the different disease stages.[1](#jvh12847-bib-0001){ref-type="ref"} Here, we explore the uncertainty arising from these factors by comparing the models used in two key papers modelling progression of chronic HCV infection. Martin et al.\'s model[2](#jvh12847-bib-0002){ref-type="ref"} informed UK guidance,[3](#jvh12847-bib-0003){ref-type="ref"} European recommendations[4](#jvh12847-bib-0004){ref-type="ref"} and an estimate of UK HCV burden,[5](#jvh12847-bib-0005){ref-type="ref"} and Harris et al.\'s model[6](#jvh12847-bib-0006){ref-type="ref"} has informed an important review[7](#jvh12847-bib-0007){ref-type="ref"} and an analysis of treatment prioritization.[8](#jvh12847-bib-0008){ref-type="ref"} Here, we compare the two models in terms of estimated health detriment (quality‐adjusted life‐year \[QALY\] loss) and costs to the health service, using a model structure that can represent both models (Figure [1](#jvh12847-fig-0001){ref-type="fig"}).

![Models describing the progression of chronic hepatitis C virus (HCV) infection. SVR, sustained virologic response. Initially, all individuals are in the state highlighted in bold. Solid lines denote states and progressions occurring in both models. Dashed lines denote progressions occurring in model B only. Dotted lines and compartments denote states and progressions included in model A only. Symbols in the top‐left corners denote the state variables used in the model equations. Both models incorporate state‐ and age‐dependent mortality (not shown for clarity)](JVH-25-514-g001){#jvh12847-fig-0001}

2. MATERIALS AND METHODS {#jvh12847-sec-0002}
========================

We implemented Markov models of HCV progression in a cohort of chronically infected individuals, as described by Martin et al[2](#jvh12847-bib-0002){ref-type="ref"} ("model A") and Harris et al[6](#jvh12847-bib-0006){ref-type="ref"} ("model B"). We consider a closed cohort and do not consider further transmission of infection or re‐infection of the cohort after treatment/recovery. The models are illustrated in Figure [1](#jvh12847-fig-0001){ref-type="fig"} with corresponding sets of equations in Supporting Information. Individuals with mild chronic HCV may progress to moderate disease, cirrhosis, decompensated cirrhosis and hepatocellular carcinoma (HCC), whereas model A uses age‐invariant annual probabilities of progression estimated by Shepherd et al,[9](#jvh12847-bib-0009){ref-type="ref"} and model B has age‐dependent probabilities (Table [S2](#jvh12847-sup-0001){ref-type="supplementary-material"}). Individuals with mild disease, moderate disease and cirrhosis receive antiviral treatment of peginterferon‐α and ribavirin at fixed rates. Patients in whom sustained virologic response (SVR) does not occur are not eligible to receive further antiviral treatment.

Parameters specifying rates of progression and treatment are in Table [S2](#jvh12847-sup-0001){ref-type="supplementary-material"},[2](#jvh12847-bib-0002){ref-type="ref"}, [6](#jvh12847-bib-0006){ref-type="ref"}, [10](#jvh12847-bib-0010){ref-type="ref"}, [11](#jvh12847-bib-0011){ref-type="ref"}, [12](#jvh12847-bib-0012){ref-type="ref"} with quality‐of‐life weights and costs in Table [S1](#jvh12847-sup-0001){ref-type="supplementary-material"}.[2](#jvh12847-bib-0002){ref-type="ref"}, [13](#jvh12847-bib-0013){ref-type="ref"}, [14](#jvh12847-bib-0014){ref-type="ref"} Cost parameters, which we inflated to 2015‐2016 UK pounds (GBP, £) using the hospital & community health services index,[15](#jvh12847-bib-0015){ref-type="ref"}, [16](#jvh12847-bib-0016){ref-type="ref"} were reported by both Martin et al[2](#jvh12847-bib-0002){ref-type="ref"} and Harris et al,[6](#jvh12847-bib-0006){ref-type="ref"} but only Martin et al[2](#jvh12847-bib-0002){ref-type="ref"} (model A) calculated QALYs and hence reported quality‐of‐life weights. We used these quality‐of‐life weights in model A and model B. Martin et al[2](#jvh12847-bib-0002){ref-type="ref"} (model A) also included health utility values for those in the process of being treated. Whilst the model does not include a compartment for those being treated, it does account for the increased QALY losses and costs for those undergoing treatment. Treatment lasts between 12 and 48 weeks depending on the HCV genotype. A proportion of individuals in mild, moderate and cirrhosis states are treated each year, and therefore, we adjust the QALYs and costs for each of these states accordingly. Rates of age‐dependent annual background mortality were obtained from life tables from the Office for National Statistics,[17](#jvh12847-bib-0017){ref-type="ref"} and quality‐of‐life norms by age were obtained from Kind et al[13](#jvh12847-bib-0013){ref-type="ref"}

We considered cohorts of 1000 individuals aged 20, 35 and 50 years at the time of nascent chronic HCV infection, comparing the incidence of progression to various health states and the associated costs and QALY losses predicted by the two models, with results presented per person or per 1000 persons according to ease of reading. The analysis is from the perspective of the National Health Service (NHS) and considered the lifetime of the patient cohort. Health utilities and costs were discounted at 3.5% p.a., as standard for the UK.[18](#jvh12847-bib-0018){ref-type="ref"}

The division between HCV genotypes as described in the two models differs, with model A differentiating between genotype 1 and all other genotypes, and model B splitting the genotypes into categories of genotype 1, 4, 5, 6 and genotype 2, 3. To compensate for this, and to better compare between the two models, we split the populations into those who are, or are not, infected with HCV genotype 1 (Table [S2](#jvh12847-sup-0001){ref-type="supplementary-material"}).

3. RESULTS {#jvh12847-sec-0003}
==========

3.1. Effect of initial age on disease burden {#jvh12847-sec-0004}
--------------------------------------------

The two models differ markedly in how initial age affects their predicted burden of HCV (Figure [2](#jvh12847-fig-0002){ref-type="fig"}). Martin et al.\'s model[2](#jvh12847-bib-0002){ref-type="ref"} ("model A" hereafter) predicts monotonically declining discounted costs and QALY losses with increasing initial age (Figure [2](#jvh12847-fig-0002){ref-type="fig"}A,B), whilst Harris et al\'s model[6](#jvh12847-bib-0006){ref-type="ref"} ("model B" hereafter) predicts discounted costs increase with initial age below 40 years and then decline slightly (Figure [2](#jvh12847-fig-0002){ref-type="fig"}A), but that discounted QALY losses change little with initial age below 40 years and then decline (Figure [2](#jvh12847-fig-0002){ref-type="fig"}B). Model A predicts higher discounted costs than model B except at initial ages \>40 years but predicts lower discounted QALY losses except at initial ages \<29 years. The age dependency of predicted discounted costs and QALY losses is much greater in model A than model B. As disease progression occurs over decades, discounting has an important effect on the net present value of costs and QALY losses, affecting not only the magnitude but also the effect of initial age: without discounting in both models, the costs and QALYs decline monotonically with increasing initial age, and model A predicts lower QALY losses for all but the very youngest initial ages (Figure [2](#jvh12847-fig-0002){ref-type="fig"}C,D).

![A, Discounted (3.5% p.a.) cumulative costs, (B) discounted (3.5% p.a.) cumulative QALY losses, (C) undiscounted cumulative costs, (D) undiscounted cumulative QALY losses, over the lifetime of the patient by initial age](JVH-25-514-g002){#jvh12847-fig-0002}

The models differ markedly in the predicted costs, burden of illness (QALY loss) and the incidence of different stages of disease---both in terms of the timing of progression and the numbers of individuals affected, which will affect the need for particular types of care. We examine these differences below.

3.2. Incidence of progression to disease states {#jvh12847-sec-0005}
-----------------------------------------------

In model A, the incidence of moderate disease is initially highest and declines monotonically over time, whereas in model B for those initially aged 20 and 35 years, the incidence fluctuates over time and is highest around 40 years of age (ie after 20 years in those initially aged 20 years and after 5 years in those initially aged 35 years), and for those initially aged 50 years, incidence is initially highest and then declines almost monotonically (Figure [3](#jvh12847-fig-0003){ref-type="fig"}).

![Incidence of disease states in cohorts of 1000 individuals with chronic HCV infection. Top, middle, bottom row: initial age 20, 35 and 50 years, respectively. Columns, left to right: model A, model B, difference (model A---model B)](JVH-25-514-g003){#jvh12847-fig-0003}

There is a striking difference between the models regarding the incidence of cirrhosis and HCC (Figure [3](#jvh12847-fig-0003){ref-type="fig"}). Trends observed in model A are similar for all initial ages, with incidence of cirrhosis peaking at 7‐8 cases per 1000 infections after roughly 20 years of infection. Incidence of HCC is low (1‐2 cases per 1000 infections per year in all 3 cohorts). In model B, the incidence of cirrhosis and HCC is much higher and has peaks occurring later (around 80 years of age for cirrhosis and a little older for HCC, regardless of initial age), and rates fluctuate over time due to patterns of age dependence.

Comparison of cumulative incidence makes clear that the models differ not only in the timing of occurrence of disease states but also in the numbers of individuals affected (Figure [4](#jvh12847-fig-0004){ref-type="fig"}). In those initially aged 20 years, overall numbers of moderate disease cases are similar but they occur earlier in model A. In those initially aged 35 years, more cases of moderate disease occur in the first 5 years in model A, but the number occurring over 10 years is similar and fewer cases occur overall in the lifetime of the patient cohort. In those initially aged 50 years, there are fewer cases in model A at all times. Model A predicts fewer cases of cirrhosis than model B for all initial ages, although for those initially aged 20 years, model A predicts substantial numbers of cirrhosis cases occurring earlier than model B. Model A predicts many fewer cases of HCC than model B, although the two models\' predictions of cumulative cases only diverge after age 65 years, regardless of initial age.

![Cumulative incidence of disease states in cohorts of 1000 individuals with chronic HCV infection. Top, middle, bottom row: initial age 20, 35 and 50 years, respectively. Columns, left to right: model A, model B, difference (model A---model B)](JVH-25-514-g004){#jvh12847-fig-0004}

Both models predict similar incidence of mild SVR (ie successful treatment among those with mild chronic infection), and in both models, the incidence is initially maximal and then declines monotonically (Figure [3](#jvh12847-fig-0003){ref-type="fig"}). It should be noted however, that for model A at least, the decrease in SVR over time is a consequence of fewer individuals being in the mild disease state rather than the efficacy of treatment decreasing with age. Cumulative incidence reflects these results, peaking at 261, 245 and 216 cases per 1000 individuals in model A, and 313, 222 and 142 cases in model B. Notice the difference in cumulative incidence is more marked in model B (Figure [4](#jvh12847-fig-0004){ref-type="fig"}).

The models\' SVR predictions are similar, but lower in those with moderate disease, with both models predicting roughly 3 cases per 1000 infections after 15 years of infection in model A, and 10‐30 years in model B for all cohorts (Figure [3](#jvh12847-fig-0003){ref-type="fig"}). Cumulative incidence decreases with age in both models (A; 134‐89, B; 132‐107) (Figure [4](#jvh12847-fig-0004){ref-type="fig"}).

Incidence of SVR in those with cirrhosis is higher in model A than in model B, peaking at roughly 2 cases per 1000 infected individuals, compared to less than 1 in model B (Figure [3](#jvh12847-fig-0003){ref-type="fig"}). Cumulative incidence is much lower in model B than in model A, decreasing from 83 to 46 in model A and increasing from 16 to 19 in model B (Figure [4](#jvh12847-fig-0004){ref-type="fig"}).

The models differ markedly in the predicted incidence of liver transplants. The total number of transplants occurring in a cohort of 1000 individuals with chronic infection initially aged 20, 35 and 50 years, respectively, is 30, 21 and 11 in model A and 39, 42 and 41 in model B. Notice model A predicts a declining incidence of transplants with increasing age whilst model B predicts no trend. The peak annual frequency of transplants in model B is more than double that of model A, with predictions for the cohort of 1000 individuals with chronic infection initially aged 20, 35 and 50 years, respectively, being 0.6, 0.5 and 0.4 in model A, and 1.2, 1.5 and 1.8 in model B, with the timing of the peak occurring later in model B (Figure [3](#jvh12847-fig-0003){ref-type="fig"}).

The two models predict different numbers of deaths due to HCV and opposite trends with initial age. Model A predicts numbers of deaths in 1000 individuals with chronic HCV initially aged 20, 35 and 50 years, respectively, being 213, 145 and 78, whilst model B predicts corresponding numbers 330, 345 and 323 (Figure [4](#jvh12847-fig-0004){ref-type="fig"}). Additionally, the peak incidence of annual mortality is 4.2, 3.7 and 2.7 in model A, and 9.6, 11.5 and 13.7 in model B. The peak occurs earlier in model B (Figure [3](#jvh12847-fig-0003){ref-type="fig"}), resulting in more life‐years and QALYs lost per death on average.

3.3. Health detriment (QALY losses) {#jvh12847-sec-0006}
-----------------------------------

The average discounted QALY loss (due to morbidity and mortality) per chronic HCV infection estimated by model A is 4.9, 4.1 and 3.1 for those initially aged 20, 35 and 50 years, respectively (Figure [2](#jvh12847-fig-0002){ref-type="fig"}B, Table [1](#jvh12847-tbl-0001){ref-type="table-wrap"}). Corresponding discounted QALY losses from model B are 4.6, 4.5 and 4.0, respectively. The models are much more different in their predicted QALY losses due to HCV‐associated mortality. Model A predicts that average discounted QALY losses due to HCV‐related mortality decrease as initial age increases, with 0.81, 0.52 and 0.25 discounted QALYs lost per chronic infection in those initially aged 20, 35 and 50 years, respectively, representing 16.5%, 12.6% and 8.1% of total discounted QALY losses, respectively (Table [1](#jvh12847-tbl-0001){ref-type="table-wrap"}). Model B has a different pattern, with average discounted QALY losses due to HCV‐related mortality being greater in those initially aged 35 years (0.93 per person) than in those initially aged 50 years (0.92), and in those initially aged 20 years (0.76). In model B, the proportion of the total discounted QALY loss that is due to HCV‐related mortality is 16.7%, 20.8% and 23.0% in individuals initially aged 20, 35 and 50 years, respectively (Table [1](#jvh12847-tbl-0001){ref-type="table-wrap"}). Also, with increasing age, there are increases in the magnitude of the differences between model A and B regarding the proportion of QALY losses attributable to different disease stages. Temporal trends in discounted and undiscounted QALY losses in the two models are shown in Figures [S1](#jvh12847-sup-0001){ref-type="supplementary-material"}‐[S4](#jvh12847-sup-0001){ref-type="supplementary-material"}.

###### 

QALY losses due to morbidity of HCV disease states incurred over the lifetimes of each cohort of 1000 individuals with chronic HCV infection initially aged 20, 35 and 50 years. QALY losses due to mortality are also shown. The percentage of the total QALY loss attributable to morbidity of each disease stage and mortality is also shown. Where applicable, the discount rate used is 3.5% p.a

  HCV disease stage                Model A   Model B   QALY--loss differences (model A---model B)                                                                                     
  -------------------------------- --------- --------- -------------------------------------------- ------ ------ ------ -------- -------- ------ ------ ------ ------ ------ ------- -------
  Discounted                                                                                                                                                                          
  Mild                             1960      1820      1590                                         40.1   44.4   50.9   1990     1600     1180   43.5   35.7   29.4   −30    220     410
  Moderate                         948       830       655                                          19.4   20.3   21.0   966      1150     1200   21.1   25.6   30.0   −18    −320    −545
  Cirrhosis                        380       311       217                                          7.8    7.6    6.9    147      211      259    3.2    4.7    6.5    233    100     −42
  Decompensated cirrhosis          87        68        45                                           1.8    1.7    1.4    43       53       54     0.9    1.2    1.4    44     15      −9
  HCC                              13        10        7                                            0.3    0.2    0.2    15       27       40     0.3    0.6    1.0    −2     −17     −33
  Transplant and post‐transplant   12        9         5                                            0.3    0.2    0.2    18       26       32     0.4    0.6    0.8    −6     −17     −27
  Mild (SVR)                       319       261       187                                          6.5    6.4    6.0    424      289      150    9.3    6.5    3.8    −105   −28     37
  Moderate (SVR)                   222       168       107                                          4.5    4.1    3.4    190      174      148    4.2    3.9    3.7    32     −6      −41
  Cirrhosis (SVR)                  144       103       59                                           3.0    2.5    1.9    18       21       21     0.4    0.5    0.5    126    82      38
  HCV‐related mortality            805       517       253                                          16.5   12.6   8.1    762      931      918    16.7   20.8   23.0   43     −414    −665
  Total                            4890      4090      3130                                                              4570     4480     4000                        320    −390    −870
  Undiscounted                                                                                                                                                                        
  Mild                             3430      3000      2430                                         23.4   30.4   40.5   3240     2350     1610   22.4   19.9   19.2   190    650     820
  Moderate                         2450      1910      1300                                         16.6   19.3   21.6   2840     2670     2130   19.6   22.6   25.2   −390   −760    −830
  Cirrhosis                        1290      896       511                                          8.8    9.1    8.5    672      695      636    4.6    5.9    7.6    618    201     −125
  Decompensated cirrhosis          333       219       114                                          2.3    2.2    1.9    180      168      135    1.2    1.4    1.6    153    51      −21
  HCC                              47        32        17                                           0.3    0.3    0.3    97       109      110    0.7    0.9    1.3    −50    −77     −93
  Transplant and post‐transplant   57        33        14                                           0.4    0.3    0.2    114      113      96     0.8    1.0    1.1    −57    −80     −82
  Mild (SVR)                       1070      716       412                                          7.3    7.3    6.9    1390     751      316    9.6    6.4    3.8    −320   −35     96
  Moderate (SVR)                   911       552       273                                          6.2    5.6    4.5    835      593      365    5.8    5.0    4.3    76     −41     −92
  Cirrhosis (SVR)                  672       377       164                                          4.6    3.8    2.7    96       83       61     0.7    0.7    0.7    576    294     103
  HCV‐related mortality            4440      2140      772                                          30.2   21.7   12.9   5020     4250     2960   34.6   36.1   35.2   −580   −2110   −2188
  Total                            14 700    9880      6000                                                              14 500   11 800   8420                        200    −1920   −2420
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Mild and moderate disease stages account for 59%‐72% of QALY losses in model A and 49%‐65% in model B, with the proportion increasing with initial age in both models (Figure [2](#jvh12847-fig-0002){ref-type="fig"}B, Table [1](#jvh12847-tbl-0001){ref-type="table-wrap"}). Up to half of all discounted QALY losses in the models are due to mild disease (Table [1](#jvh12847-tbl-0001){ref-type="table-wrap"}). Model A predicts average losses per person of 1.96, 1.82 and 1.59 in the mild stage in those initially aged 20, 35 and 50 years, respectively, representing 40%, 44% and 51% of all discounted QALY losses, respectively. In model B, the corresponding figures are 1.99 (44%), 1.60 (36%) and 1.18 (29%), respectively. In both models, the QALY losses associated with mild disease decline with increasing initial age, whereas the proportion of total QALY loss increases with initial age in model A but declines in model B.

Moderate disease accounts for a large proportion of QALY losses (Table [1](#jvh12847-tbl-0001){ref-type="table-wrap"}). The discounted QALY losses (and proportion of total discounted QALY losses) associated with moderate disease in those initially aged 20, 35 and 50 years are 0.95 (19.4%), 0.83 (20.3%) and 0.66 (21.0%) per person in model A, and 0.97 (21.1%), 1.15 (26.5%) and 1.20 (30.0%) in model B. In both models, the proportion of total discounted QALY loss increases with initial age, whereas the discounted QALY losses decline with increasing initial age in model A but increase in model B.

Quality‐adjusted life‐years losses due to cirrhosis decline with increasing initial age in model A whilst increasing in model B (Table [1](#jvh12847-tbl-0001){ref-type="table-wrap"}). There are also substantial differences in the magnitude of QALY losses. The difference is greatest for those initially aged 20 years, with discounted QALY losses predicted by model A (0.38 per person) being more than double compared to model B (0.15). For individuals initially aged 35 years, model A predicts discounted QALY losses (0.31) that are 47% greater than model B (0.21). In contrast, for individuals initially aged 50 years, model A predicts discounted QALY losses (0.22) that are 16% less than model B (0.26). Similar patterns are seen with decompensated cirrhosis.

Hepatocellular carcinoma causes similar discounted QALY losses in those initially aged 20 years in each model (13 per 1000 individuals in model A, 15 in model B), but in model A, the loss decreases with increasing initial age, whilst in model B it increases, being 10 in model A and 27 in model B in those initially aged 35 years, and 7 in model A and 40 in model B in those initially aged 50 years (Table [1](#jvh12847-tbl-0001){ref-type="table-wrap"}).

3.4. Costs {#jvh12847-sec-0007}
----------

The cumulative discounted cost per chronic HCV infection declines with increasing initial age in model A (£19 200, £17 100 and £13 800 in those initially aged 20, 35 and 50 years, respectively), whereas in model B, costs increase slightly with initial age (£13 900, £15 100 and £15 300 in those initially aged 20, 35 and 50 years, respectively) (Table [2](#jvh12847-tbl-0002){ref-type="table-wrap"}). Temporal trends in discounted and undiscounted costs in the two models are shown in Figures [S5](#jvh12847-sup-0001){ref-type="supplementary-material"}‐[S8](#jvh12847-sup-0001){ref-type="supplementary-material"}.

###### 

Costs of HCV disease states incurred over the lifetime of the average individual with chronic HCV infection initially aged 20, 35 and 50 years, calculated by each model. The percentage of the total discounted cost attributable to each disease stage is also shown. Where applicable, the discount rate used is 3.5%p.a

                                   Model A   Model B   Cost differences (model A---model B)                                                                                         
  -------------------------------- --------- --------- -------------------------------------- ------ ------ ------ -------- -------- -------- ------ ------ ------ -------- ------- -------
  Discounted                                                                                                                                                                        
  Mild                             2520      2450      2270                                   13.1   14.3   16.4   4280     3580     2780     30.9   23.8   18.1   −1760    −1130   −510
  Moderate                         3680      3390      2810                                   19.2   19.8   20.4   4430     5490     5980     32.0   36.4   39.1   −750     −2100   −3170
  Cirrhosis                        1880      1610      1180                                   9.8    9.4    8.6    864      1290     1660     6.2    8.5    10.8   1016     320     −480
  Decompensated cirrhosis          2650      2190      1490                                   13.8   12.8   10.8   1330     1680     1790     9.5    11.2   11.7   1320     510     −300
  HCC                              351       296       209                                    1.8    1.7    1.5    447      789      1200     3.2    5.2    7.9    −96      −493    −991
  Transplant and post‐transplant   442       357       234                                    2.3    2.1    1.7    428      662      894      3.0    4.4    5.8    14       −305    −660
  Mild (SVR)                       4050      3800      3370                                   21.1   22.2   24.4   1680     1190     649      12.1   7.9    4.2    2370     2610    2721
  Moderate (SVR)                   2210      1910      1460                                   11.5   11.1   10.6   370      355      311      2.7    2.4    2.0    1840     1555    1149
  Cirrhosis (SVR)                  1400      1130      763                                    7.3    6.6    5.5    25       31       32       0.2    0.2    0.2    1375     1099    31
  Total                            19 200    17 100    13 800                                                      13 900   15 100   15 300                        5300     2000    −1500
  Undiscounted                                                                                                                                                                      
  Mild                             4550      4150      3530                                   7.9    9.7    12.6   7000     5280     3810     16.2   13.7   12.2   −2450    −1130   −280
  Moderate                         9900      8050      5700                                   17.3   18.8   20.4   13 400   12 900   10 700   31.0   33.7   34.3   −3500    −4850   −5000
  Cirrhosis                        6690      4800      2840                                   11.7   11.2   10.2   4040     4300     4090     9.4    11.2   13.1   2650     500     −1250
  Decompensated cirrhosis          10 500    7180      3890                                   18.4   16.8   13.9   5740     5480     4550     13.3   14.3   14.6   4760     1700    −660
  HCC                              1320      925       525                                    2.3    2.2    1.9    2840     3220     3290     6.6    8.4    10.5   −1520    −2295   −2765
  Transplant and post‐transplant   1870      1220      626                                    3.3    2.9    2.2    2450     2600     2460     5.7    6.8    7.9    −580     −1380   −1834
  Mild (SVR)                       9180      7480      5680                                   16.0   17.5   20.3   5810     3210     1400     13.5   8.4    4.5    3370     4270    4280
  Moderate (SVR)                   7550      5300      3220                                   13.2   12.4   11.5   1700     1240     781      4.0    3.2    2.5    5850     4060    2439
  Cirrhosis (SVR)                  5820      3700      1940                                   10.1   8.7    6.9    142      126      94       0.3    0.3    0.3    5678     3574    1846
  Total                            57 400    42 800    27 900                                                      43 100   38 400   31 200                        14 300   4400    −3300
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Differences between the models are only partially due to the models having different unit costs. When model A\'s unit costs are used in model B, the predicted discounted costs are higher than using model B\'s unit costs, being £16 100, £17 300 and £17 300 in those initially aged 20, 35 and 50 years, respectively (Table [S3](#jvh12847-sup-0001){ref-type="supplementary-material"}). When using model B\'s unit costs in model A, the average discounted cost in persons initially aged 20, 35 and 50 years is £16 100, £14 400 and £11 700, respectively (Table [S4](#jvh12847-sup-0001){ref-type="supplementary-material"}). Note that the trends with initial age were unchanged in each model.

Mild and moderate disease stages account for only one‐third of the total discounted cost in model A, whilst accounting for majority of the total cost (\>57%) in model B (Table [2](#jvh12847-tbl-0002){ref-type="table-wrap"}), particularly in the younger ages. If the unit costs from model A are used in model B (Table [S3](#jvh12847-sup-0001){ref-type="supplementary-material"}), then mild and moderate disease stages still account for more than half of the total cost, and if the unit costs from model B are applied to model A (Table [S4](#jvh12847-sup-0001){ref-type="supplementary-material"}), then mild and moderate stages account for \~40% of the total cost, which is still much less than in model B.

Costs due to mild disease decrease with increasing initial age in both models, but the proportion of total costs that they represent increases with initial age in model A whilst declining in model B (Table [2](#jvh12847-tbl-0002){ref-type="table-wrap"}). Costs due to moderate disease decrease with increasing initial age in model A and represent a slightly increasing proportion of total costs; in model B, these costs and the proportion of total costs that they represent both increase with increasing initial age (Table [2](#jvh12847-tbl-0002){ref-type="table-wrap"}). These patterns occur regardless of which set of unit costs is used (Table [2](#jvh12847-tbl-0002){ref-type="table-wrap"}, Tables [S3](#jvh12847-sup-0001){ref-type="supplementary-material"} and [S4](#jvh12847-sup-0001){ref-type="supplementary-material"}).

The average discounted costs per patient incurred due to cirrhosis, decompensated cirrhosis, HCC and liver transplantation decrease with increasing initial age in model A, as do the proportions of total discounted costs that they represent (Table [2](#jvh12847-tbl-0002){ref-type="table-wrap"}); the opposite is the case in model B. The models differ greatly in the predicted costs due to cirrhosis and decompensated cirrhosis in individuals initially aged 20 years, with the cost in model A being approximately double that in model B. The difference declines with increasing initial age, and in those initially aged 50 years, costs in model A are lower, being 71% and 83% of the costs in model B for cirrhosis and decompensated cirrhosis, respectively. Average costs due to HCC are moderately different in the two models in those initially aged 20 years (£351 in model A, £447 in model B) but markedly different in those initially aged 35 years (£296 in model A, £789 in model B) and very different in those initially aged 50 years (£209 in model A, £1200 in model B). Costs due to transplantation are similar in the two models in those initially aged 20 years (£442 in model A, £428 in model B) but markedly different in those initially aged 35 years (£357 in model A, £662 in model B) and very different in those initially aged 50 years (£234 in model A, £894 in model B).

4. DISCUSSION {#jvh12847-sec-0008}
=============

There are important differences between the models that we compared in the predicted burden of disease and cost to the health service arising from chronic HCV infection. Model A (Martin et al[2](#jvh12847-bib-0002){ref-type="ref"}) predicted generally lower average discounted QALY losses per person (3.1‐4.9 vs 4.0‐4.6; Table [1](#jvh12847-tbl-0001){ref-type="table-wrap"}) and higher average discounted costs (£13 800‐£19 200 vs £13 900‐£15 300; Table [2](#jvh12847-tbl-0002){ref-type="table-wrap"}) than model B (Harris et al[6](#jvh12847-bib-0006){ref-type="ref"}). The unit cost estimates derived from Harris et al[6](#jvh12847-bib-0006){ref-type="ref"} were slightly lower, except for treatment of mild and moderate disease and cirrhosis (Table [S1](#jvh12847-sup-0001){ref-type="supplementary-material"}), but this was not the major reason for the difference in calculated costs. The two models differ markedly in how the initial age affects their results, with progression rates being age‐dependent in Harris et al[6](#jvh12847-bib-0006){ref-type="ref"} but not in Martin et al[2](#jvh12847-bib-0002){ref-type="ref"} (Table [S2](#jvh12847-sup-0001){ref-type="supplementary-material"}). Model A predicts that costs and QALY losses decline with increasing initial age whilst model B predicts little change or increases with increasing initial age up to 40 years, followed by declines with increasing age. In both models, a large proportion of the costs of HCV infection are due to the mild and moderate disease stages, which involve a large proportion of the infected individuals and have long average duration. Model B predicts much greater numbers of liver transplants, which is important given the limited availability of livers for transplant, and the increasing need for transplants due to obesity‐ and alcohol‐related liver damage.

The uncertainties highlighted by our analysis have important consequences for UK public health planning regarding HCV, as they affect the magnitude and timing of the expected demand for care over the coming years and decades, and the cost‐effectiveness of interventions to against HCV infection and disease. Current NICE guidelines[3](#jvh12847-bib-0003){ref-type="ref"} are based on Martin et al\'s model,[2](#jvh12847-bib-0002){ref-type="ref"} which is based on the work of Shepherd et al[9](#jvh12847-bib-0009){ref-type="ref"} Importantly, we have shown that Harris et al\'s model,[6](#jvh12847-bib-0006){ref-type="ref"} with estimates of progression rates that are age‐dependent, produces different estimates of costs and QALY losses due to chronic HCV. As Harris et al\'s analysis[6](#jvh12847-bib-0006){ref-type="ref"} found that rates differ by age, this should be considered in future modelling analyses.

A strength of this study is its systematic comparison of the models, examining the importance of age‐dependent progression rates and different estimates of unit costs in contributing to uncertainty. The marked differences between the models of Martin et al[2](#jvh12847-bib-0002){ref-type="ref"} and Harris et al[6](#jvh12847-bib-0006){ref-type="ref"} are due primarily to differences in progression rates, which determine numbers of individuals in each disease state, and differences in rates of health service utilization associated with each disease state, rather than differences in estimated unit costs to the health service of treating each health state. Further study of progression rates---and factors associated with variation, such as age---and rates of health service utilization associated with different stages of HCV‐associated disease is required.

There are other important gaps in knowledge that require further empirical study. As progression from chronic HCV infection through disease states can take decades, the life expectancy of infected individuals could be an important determinant of the cost‐effectiveness of treatment. People who inject drugs (PWID) are an important risk group for HCV infection and make up the majority of those infected with HCV in the UK.[15](#jvh12847-bib-0015){ref-type="ref"}, [16](#jvh12847-bib-0016){ref-type="ref"} Treatment as Prevention (TasP) has been advocated for this group, although there are important uncertainties in its likely effectiveness, which depends upon the structure of the network of injecting partners, the coverage of testing and proportion of infected patients who are treated and cured, and the frequency of behaviour change preventing re‐infection after successful treatment.[21](#jvh12847-bib-0021){ref-type="ref"} Further studies of all of these are required, including analysis of potential synergistic effects[22](#jvh12847-bib-0022){ref-type="ref"} of combining HCV TasP with needle and syringe programmes (which reduce the infection risk of injecting) and opiate substitution therapy (which assist PWID in stopping injecting). Use of transmission dynamic models to analyse surveillance data is important in assessing population‐level impacts of interventions;[23](#jvh12847-bib-0023){ref-type="ref"} in the case of PWID, it is important to use models that account for the injecting network structure and dynamics.[21](#jvh12847-bib-0021){ref-type="ref"} In some marginalised populations, proactive "find and treat" services may be cost‐effective or even cost‐saving, as has been found for tuberculosis.[24](#jvh12847-bib-0024){ref-type="ref"}, [25](#jvh12847-bib-0025){ref-type="ref"} Past history of drug injection may reduce life expectancy independent of HCV infection; if so, then this would reduce the cost‐effectiveness of treatment for chronic HCV in that patient group. However, if comorbidities associated with a history of drug injection increase rates of progression to later‐stage disease, then this would tend to increase cost‐effectiveness of treatment. Factors that should also be taken into consideration when calculating the cost‐effectiveness of treatment are alcohol consumption, gender and co‐infection, as each have been found to vary HCV disease progression rates,[26](#jvh12847-bib-0026){ref-type="ref"}, [27](#jvh12847-bib-0027){ref-type="ref"} and also affect life expectancy. We recommend studies of patient health records to determine the rates of health service utilization---both primary and secondary care---by patients in different stages of disease and with different comorbidities. Importantly, actual patient pathways can be different from idealised pathways typically used in economic evaluations, and there can be considerable variation between patients (eg see Ref. [28](#jvh12847-bib-0028){ref-type="ref"}). Finally, the impact on disease progression and health service utilization in individuals treated with direct acting antivirals (DAAs), which are highly efficacious and well‐tolerated but are also expensive, requires further study to determine how to use DAAs in a cost‐effective manner. However, if the price paid for DAAs is too high, then this damages overall population health because the money could be used in another way to obtain a greater health gain.

In summary, this research has emphasised the uncertainty in the health burden and economic cost of HCV disease in the UK. The main source of uncertainty is progression rates between disease states and associated rates of health service utilization, particularly with regard to age dependency. In addition, the effects of other risk factors and comorbidities require quantification to improve information for planning and decision‐making.
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